cilostazol has been researched along with Insulin Sensitivity in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats." | 7.71 | The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. ( Ahn, YB; Cha, BY; Chang, SA; Han, JH; Kang, MI; Kang, SK; Lee, JM; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH, 2001) |
| "Body weight and abdominal fat was increased in OLETF rats but cilostazol supplementation did not alter them." | 7.70 | Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM. ( Harada, N; Minami, A; Nakamura, T; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S, 1999) |
| "We evaluated association between hyperinsulinemia/insulin resistance and microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rat." | 5.32 | Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. ( Oshiro, Y; Shimabukuro, M; Shimajiri, Y; Takasu, N; Tohma, T; Yamakawa, M, 2004) |
| "These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats." | 3.71 | The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. ( Ahn, YB; Cha, BY; Chang, SA; Han, JH; Kang, MI; Kang, SK; Lee, JM; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH, 2001) |
| "Body weight and abdominal fat was increased in OLETF rats but cilostazol supplementation did not alter them." | 3.70 | Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM. ( Harada, N; Minami, A; Nakamura, T; Nakaya, Y; Niwa, Y; Ohnaka, M; Sakamoto, S, 1999) |
| "Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease linked to insulin resistance, oxidative stress, and cytokine imbalance." | 1.56 | Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats. ( Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA, 2020) |
| "We evaluated association between hyperinsulinemia/insulin resistance and microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rat." | 1.32 | Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. ( Oshiro, Y; Shimabukuro, M; Shimajiri, Y; Takasu, N; Tohma, T; Yamakawa, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| El-Deen, RM | 1 |
| Heeba, GH | 1 |
| Abdel-Latif, RG | 1 |
| Khalifa, MMA | 1 |
| Wada, T | 1 |
| Onogi, Y | 1 |
| Kimura, Y | 1 |
| Nakano, T | 1 |
| Fusanobori, H | 1 |
| Ishii, Y | 1 |
| Sasahara, M | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Birnbaum, Y | 1 |
| Nanhwan, MK | 1 |
| Ling, S | 1 |
| Perez-Polo, JR | 1 |
| Ye, Y | 1 |
| Bajaj, M | 1 |
| Tohma, T | 1 |
| Shimabukuro, M | 1 |
| Oshiro, Y | 1 |
| Yamakawa, M | 1 |
| Shimajiri, Y | 1 |
| Takasu, N | 1 |
| Nakaya, Y | 1 |
| Minami, A | 1 |
| Sakamoto, S | 1 |
| Niwa, Y | 1 |
| Ohnaka, M | 1 |
| Harada, N | 1 |
| Nakamura, T | 1 |
| Chang, SA | 1 |
| Cha, BY | 1 |
| Yoo, SJ | 1 |
| Ahn, YB | 1 |
| Song, KH | 1 |
| Han, JH | 1 |
| Lee, JM | 1 |
| Son, HS | 1 |
| Yoon, KH | 1 |
| Kang, MI | 1 |
| Lee, KW | 1 |
| Son, HY | 1 |
| Kang, SK | 1 |
6 other studies available for cilostazol and Insulin Sensitivity
| Article | Year |
|---|---|
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Topics: Animals; Antioxidants; Biomarkers; Cilostazol; Diet, High-Fat; Fatty Liver; Inflammation; Insulin; I | 2020 |
Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Chronic Disease; Cilostazol; Diabetes Mellitus, E | 2013 |
PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins.
Topics: Animals; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Diet, Western; Fluorobenzenes; Gene K | 2014 |
Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat.
Topics: Albuminuria; Animals; Blood Glucose; Cilostazol; Collagen Type I; Diabetic Nephropathies; Fibronecti | 2004 |
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Topics: Abdomen; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cilostazol; Diabetes Mellitus, Type 2; | 1999 |
The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus.
Topics: Animals; Animals, Newborn; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Disease Models, Ani | 2001 |